Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF plus low-dose decitabine to prevent relapse after allo-HSCT in high-risk AML
ChiCTR-IIR-16008182Phase 2Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: relapse. Planned start Apr 2016; status: not yet recruiting.
02
Drugs
decitabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-16008182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008182.